Functional Antithrombin Levels in HIV/AIDS Patients at Ibadan, Nigeria
Central African Journal of Public Health
Volume 5, Issue 5, October 2019, Pages: 198-202
Received: Jun. 25, 2019; Accepted: Jul. 30, 2019; Published: Aug. 26, 2019
Views 77      Downloads 21
Authors
Olutogun Tolulase Aderayo, Department of Haematology and Blood Transfusion, Bowen University, Iwo, Nigeria
Fasola Foluke Atinuke, Department of Haematology and Blood Transfusion, College of Medicine, University of Ibadan, Ibadan, Nigeria
Olufemi-Aworinde Kehinde Joyce, Department of Haematology and Blood Transfusion, Bowen University, Iwo, Nigeria
Aken’ova Yetunde Adebisi, Department of Haematology and Blood Transfusion, College of Medicine, University of Ibadan, Ibadan, Nigeria
Article Tools
Follow on us
Abstract
HIV infected patients have an increased incidence of venous thromboembolism and an important risk factor is antithrombin deficiency. Currently it is estimated that 10% of HIV/AIDS patients who developed venous thromboembolism had antithrombin deficiency with functional antithrombin levels less than 70%. The purpose of this study is to measure functional antithrombin levels in HIV patients prior to development of venous thromboembolic disorder. One hundred and twenty HIV positive and one hundred and twenty-six HIV negative apparently healthy blood donors were studied. Socio-demographic, medical history and clinical characteristics were obtained from the patients. Blood was analyzed for CD4+ lymphocytes count, full blood count and functional antithrombin levels. We also investigated the relationship between functional levels of antithrombin, CD4 + lymphocytes count and some haematological parameters. The functional antithrombin levels were significantly reduced in the people living with HIV/AIDS (72.6%) when compared with the controls (93.7%). There was no correlation between CD4 + lymphocytes count (by proxy the stage of the disease) and functional antithrombin levels in HIV positive patients (r = 0.02, p = 0.9). Patients with HIV infection have a mild deficiency of functional antithrombin that may lead to hypercoagulability.
Keywords
Functional, Antithrombin, HIV
To cite this article
Olutogun Tolulase Aderayo, Fasola Foluke Atinuke, Olufemi-Aworinde Kehinde Joyce, Aken’ova Yetunde Adebisi, Functional Antithrombin Levels in HIV/AIDS Patients at Ibadan, Nigeria, Central African Journal of Public Health. Vol. 5, No. 5, 2019, pp. 198-202. doi: 10.11648/j.cajph.20190505.13
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Geiben-Lynn R, Brown N, Walker BD, Luster AD. Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor. J Biol Chem. 2002; 277 (44): 42352-42357.
[2]
Saber AA, Aboolian A, Laraja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg. 2001; 67 (7): 645-647.
[3]
Huntington JA. Serpin structure, function and dysfunction. J Thromb Haemost. 2011; 9: 26-34.
[4]
Patella FJ, Delany JR, moorland AC, Fuhrer J. Declining morbidity and mortality amongst patients with advanced HIV. N Engl J Med. 1998; 338: 853-860.
[5]
John P. Greer JF, John N. Lukens, Editor. Wintrope's Clinical Heamatology. 11th Ed. New York: Lippincott Williams and Wilkins; 2003: 688-690.
[6]
Blajchman MA. An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coagul Fibrinolysis1994 Suppl 1: S5-11; discussion S59-S64.
[7]
Victor Hoffbrand DC, Edward G. D. Tuddenham, editor. Postgraduate Heamatology. 5th ed. New York: Blackwell and wiley; 2005: 378-399.
[8]
Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010; 55 (2): 262-270.
[9]
Maclean PS. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs. 2007; 67 (10): 1429-1440.
[10]
Delluc A, Le-Ven F, Mottier D, Le-Gal G. Epidemiology and risk factors of venous thromboembolism. Rev Mal Respir. 2012; 29 (2): 254-266.
[11]
Summer LM, Marso SP, Grant PJ. Atherothrombosis, thrombolysis and anti-platelet. In: Hoffbrand AV, Catovsky, Tuddenham EG, editors. Postgraduate Haematology. 5th ed. New-Delhi: Wiley; 2005: pp945-965.
[12]
Saif M, Bona R, Greenberg M. A Retrospective Study of 131 HIV infected Patients. AIDS PATIENTS CARE and STD. 2001; 15 (6): 311-324.
[13]
Sule A, Pandit N, Handa P, Chadachan V, Tan E, Sum FN et al. Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study. J Angiol. 2013; 22 (2): 95-100.
[14]
Bibas M, Biava G, Antinori A. HIV-Associated Venous Thromboembolism. Mediterr J Hematol Infect Dis. 2011; 3 (1): 1-26.
[15]
Cao YZ, Dieterich D, Thomas PA, Huang YX, Mirabile M. Identification and quantitation of HIV1 in the liver of patients with AIDS. AIDS. 1992; 6 (1): 65-70.
[16]
Huffert F, SChmitz J, Schreiber M, Schmitz H, Racz P and von Laer D. Human Kupffer cell Infected with HIV-1 In Vivo. J Acquir Immune Defic Syndr. 1993; 6: 74-79.
[17]
George SL, Swindells S, Knudson R, Stapleton JT. Unexplained Thrombosis in HIV-infected Patients Receiving Protease Inhibitors: Report of Seven Cases. Am J Med 1999; 107 (6): 624-626.
[18]
Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic Complications in Patient Infected with HIV in the Era of Highly Active antiretroviral therapy. A case series. HIV/AIDS. 2004; 39: 1214-1226.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186